CRISPR Therapeutics AG $CRSP Stock: Shah Wealth Advisors LLC Raises Position

Shah Wealth Advisors LLC increased its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 61.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 111,328 shares of the company’s stock after acquiring an additional 42,268 shares during the period. CRISPR Therapeutics comprises 1.2% of Shah Wealth Advisors LLC’s holdings, making the stock its 21st largest position. Shah Wealth Advisors LLC’s holdings in CRISPR Therapeutics were worth $6,159,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the stock. Russell Investments Group Ltd. lifted its holdings in CRISPR Therapeutics by 178.8% in the third quarter. Russell Investments Group Ltd. now owns 212,645 shares of the company’s stock valued at $11,764,000 after acquiring an additional 136,379 shares during the period. Swiss National Bank boosted its position in CRISPR Therapeutics by 5.1% in the 1st quarter. Swiss National Bank now owns 169,700 shares of the company’s stock worth $8,073,000 after purchasing an additional 8,200 shares in the last quarter. Affinity Asset Advisors LLC purchased a new stake in CRISPR Therapeutics in the 1st quarter worth approximately $7,136,000. Congress Asset Management Co. grew its stake in shares of CRISPR Therapeutics by 1.6% during the 3rd quarter. Congress Asset Management Co. now owns 111,230 shares of the company’s stock worth $6,153,000 after purchasing an additional 1,777 shares during the period. Finally, KBC Group NV grew its stake in shares of CRISPR Therapeutics by 3,999.9% during the 1st quarter. KBC Group NV now owns 116,847 shares of the company’s stock worth $5,558,000 after purchasing an additional 113,997 shares during the period. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

CRSP has been the subject of several recent research reports. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $55.00 target price on shares of CRISPR Therapeutics in a report on Thursday, August 6th. Citigroup boosted their target price on shares of CRISPR Therapeutics from $88.00 to $90.00 and gave the company a “buy” rating in a research note on Wednesday, November 4th. Citizens Jmp reissued a “market outperform” rating and set a $80.00 price target on shares of CRISPR Therapeutics in a report on Monday, August 31st. UBS Group assumed coverage on shares of CRISPR Therapeutics in a research report on Thursday, October 15th. They set a “neutral” rating and a $52.00 price target on the stock. Finally, William Blair upgraded shares of CRISPR Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 23rd. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $72.93.

Check Out Our Latest Report on CRSP

CRISPR Therapeutics Price Performance

Shares of CRISPR Therapeutics stock opened at $42.24 on Monday. The firm has a market cap of $4.10 billion, a PE ratio of -8.91 and a beta of 1.92. CRISPR Therapeutics AG has a twelve month low of $41.75 and a twelve month high of $63.45. The company has a quick ratio of 16.21, a current ratio of 16.21 and a debt-to-equity ratio of 0.36. The business has a 50-day moving average price of $52.09 and a 200 day moving average price of $52.54.

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last issued its quarterly earnings results on Monday, November 2nd. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.09). CRISPR Therapeutics had a negative return on equity of 25.59% and a negative net margin of 1,812.07%. The business had revenue of $12.67 million for the quarter, compared to analysts’ expectations of $14.75 million. The company’s quarterly revenue was up 1311.1% compared to the same quarter last year. Sell-side analysts predict that CRISPR Therapeutics AG will post -4.54 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Samarth Kulkarni sold 47,837 shares of the stock in a transaction that occurred on Monday, October 19th. The stock was sold at an average price of $49.78, for a total transaction of $2,381,325.86. Following the transaction, the chief executive officer owned 311,899 shares in the company, valued at $15,526,332.22. This trade represents a 13.30% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Ali Behbahani sold 13,679 shares of the stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $57.09, for a total value of $780,934.11. Following the transaction, the director owned 16,637 shares in the company, valued at $949,806.33. This trade represents a 45.12% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 93,558 shares of company stock valued at $4,881,663 over the last ninety days. 5.20% of the stock is owned by corporate insiders.

CRISPR Therapeutics Company Profile

(Free Report)

CRISPR Therapeutics AG is a biotechnology company focused on developing gene-based medicines using CRISPR/Cas9, a gene-editing technology that can make targeted changes to DNA. Founded in 2013, the company is headquartered in Zug, Switzerland, and maintains U.S. operations in Cambridge, Massachusetts. Its lead product, Casgevy (exa-cel), was developed with Vertex Pharmaceuticals for people with sickle cell disease and transfusion-dependent beta thalassemia. It was the first therapy based on CRISPR gene editing to receive regulatory approval.

Read More

Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report).

Institutional Ownership by Quarter for CRISPR Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.